Lowest-Rated StocksLowest-RatedNASDAQ:VIGL Vigil Neuroscience (VIGL) Stock Price, News & Analysis $8.06 +0.01 (+0.06%) As of 03:30 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Vigil Neuroscience Stock (NASDAQ:VIGL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Vigil Neuroscience alerts:Sign Up Key Stats Today's Range$8.05▼$8.1050-Day Range$7.86▼$8.0852-Week Range$1.31▼$8.10Volume2.67 million shsAverage Volume1.14 million shsMarket Capitalization$384.14 millionP/E RatioN/ADividend YieldN/APrice Target$10.80Consensus RatingHold Company Overview Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts. Read More Vigil Neuroscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreVIGL MarketRank™: Vigil Neuroscience scored higher than 63% of companies evaluated by MarketBeat, and ranked 355th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingHold Consensus RatingVigil Neuroscience has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 10 hold ratings, and no sell ratings.Amount of Analyst CoverageVigil Neuroscience has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Vigil Neuroscience's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Vigil Neuroscience are expected to grow in the coming year, from ($2.07) to ($2.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vigil Neuroscience is -3.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vigil Neuroscience is -3.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVigil Neuroscience has a P/B Ratio of 4.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Vigil Neuroscience's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.40% of the float of Vigil Neuroscience has been sold short.Short Interest Ratio / Days to CoverVigil Neuroscience has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vigil Neuroscience has recently increased by 314.26%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVigil Neuroscience does not currently pay a dividend.Dividend GrowthVigil Neuroscience does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.40% of the float of Vigil Neuroscience has been sold short.Short Interest Ratio / Days to CoverVigil Neuroscience has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vigil Neuroscience has recently increased by 314.26%, indicating that investor sentiment is decreasing significantly. News and Social Media1.9 / 5News Sentiment0.47 News SentimentVigil Neuroscience has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Vigil Neuroscience this week, compared to 2 articles on an average week.Search Interest5 people have searched for VIGL on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Vigil Neuroscience insiders have not sold or bought any company stock.Percentage Held by Insiders18.01% of the stock of Vigil Neuroscience is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions83.64% of the stock of Vigil Neuroscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vigil Neuroscience's insider trading history. Receive VIGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vigil Neuroscience and its competitors with MarketBeat's FREE daily newsletter. Email Address VIGL Stock News HeadlinesVIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil Neuroscience, Inc. - VIGLJuly 14, 2025 | businesswire.comVigil Neuroscience, Inc. (VIGL) Cash Flow - Yahoo FinanceJuly 2, 2025 | finance.yahoo.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing something much bigger: There's a new way to collect income from gold.August 4 at 2:00 AM | Investors Alley (Ad)Wall Street Analysts See a 26.1% Upside in Vigil Neuroscience (VIGL): Can the Stock Really Move This High? - NasdaqJune 27, 2025 | nasdaq.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of ShareholdersJune 9, 2025 | prnewswire.comVigil Neuroscience halts Phase 2 trial for ALSP treatmentJune 5, 2025 | investing.comVIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors ...June 5, 2025 | morningstar.comMVIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors to Contact the FirmJune 4, 2025 | prnewswire.comSee More Headlines VIGL Stock Analysis - Frequently Asked Questions How have VIGL shares performed this year? Vigil Neuroscience's stock was trading at $1.70 at the beginning of the year. Since then, VIGL shares have increased by 375.0% and is now trading at $8.0750. How were Vigil Neuroscience's earnings last quarter? Vigil Neuroscience, Inc. (NASDAQ:VIGL) released its earnings results on Wednesday, May, 7th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.53) by $0.04. When did Vigil Neuroscience IPO? Vigil Neuroscience (VIGL) raised $112 million in an initial public offering (IPO) on Friday, January 7th 2022. The company issued 7,000,000 shares at a price of $15.00-$17.00 per share. Who are Vigil Neuroscience's major shareholders? Top institutional shareholders of Vigil Neuroscience include Credit Industriel ET Commercial (0.17%), New York Life Investment Management LLC (0.11%), FNY Investment Advisers LLC (0.06%) and Deltec Asset Management LLC (0.06%). Insiders that own company stock include Ivana Magovcevic-Liebisch, Haeberlein Samantha L Budd and Spyros Papapetropoulos. View institutional ownership trends. How do I buy shares of Vigil Neuroscience? Shares of VIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vigil Neuroscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vigil Neuroscience investors own include NVIDIA (NVDA), Meta Platforms (META), Exxon Mobil (XOM), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Tesla (TSLA) and Home Depot (HD). Company Calendar Last Earnings5/07/2025Today8/04/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VIGL CIK1827087 Webvigilneuro.com Phone857-254-4445FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Price Target for Vigil Neuroscience$10.80 High Price Target$22.00 Low Price Target$8.00 Potential Upside/Downside+33.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($2.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$84.26 million Net MarginsN/A Pretax MarginN/A Return on Equity-111.70% Return on Assets-74.67% Debt Debt-to-Equity RatioN/A Current Ratio2.97 Quick Ratio2.97 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.75 per share Price / Book4.61Miscellaneous Outstanding Shares47,690,000Free Float39,099,000Market Cap$385.10 million OptionableNot Optionable Beta3.33 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:VIGL) was last updated on 8/4/2025 by MarketBeat.com Staff From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vigil Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vigil Neuroscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.